EGIS 11150

Drug Profile

EGIS 11150

Alternative Names: E-11150; EGIS-11150; S-36549

Latest Information Update: 14 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Egis Pharmaceuticals
  • Developer Egis Pharmaceuticals; Servier
  • Class Antipsychotics; Ketones; Pyridazines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor modulators; Dopamine D2 receptor modulators; Serotonin 2A receptor modulators; Serotonin-7 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psychotic disorders

Most Recent Events

  • 03 Sep 2008 Phase-I clinical trials in Psychotic disorders in Europe (unspecified route)
  • 23 Nov 2007 Pharmacodynamics data from a preclinical study presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top